FDA Confirms Direct Review Path For Aquestive's Allergy Treatment
Thursday, 4 September 2025 ()
The U.S. Food and Drug Administration (FDA) on Thursday informed Aquestive Therapeutics, Inc. (NASDAQ:AQST) that an advisory committee meeting is not required for Anaphylm (dibutepinephrine) Sublingual Film. The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains Januaryβ¦
|
||||
|
|
||||
You Might Like |
||||
